Safe and scalable vlp-based IBV vaccine for poultry
A novel VLP-based vaccine platform using engineered nodavirus capsid proteins to present IBV antigens, ensuring safety, stability, and broad immune response in poultry.
Overview
This innovative VLP-based vaccine technology utilizes engineered M. rosenbergii nodavirus capsid proteins to display antigens from infectious bronchitis virus (IBV), offering a safe and effective vaccination solution for poultry. The chimeric nodavirus capsid proteins self-assemble into stable virus-like particles (VLPs) around 30 nm in size, effectively presenting IBV epitopes to induce broad cross-reactive immune responses. The platform provides a non-replicative and non-infectious vaccine alternative, addressing safety concerns associated with live or inactivated vaccines.
Technical specifications
- Self-assembly and stability: The nodavirus capsid proteins are engineered to self-assemble into stable VLPs, maintaining integrity and functionality.
- Antigen presentation: VLPs stably present foreign antigens, including IBV epitopes, without compromising particle stability.
- Immune response: Induces broad immune responses, providing in vivo protective efficacy in challenge models for mice and chickens.
- Safety profile: The VLPs are non-replicative and non-infectious, eliminating risks related to pathogenicity or incomplete inactivation.
- Manufacturing: Produced using E. coli and Sf9 insect cells for scalability and cost-effectiveness.
Technology readiness level
The VLP-based IBV vaccine is currently at Technology Readiness Level 3, with ongoing development through systematic phases covering antigen discovery, molecular construction, characterization, immunogenicity evaluation, cross-variant reactivity assessment, and safety monitoring.
About Universiti Putra Malaysia
Universiti Putra Malaysia (UPM) is a comprehensive public research university in Serdang, Greater Kuala Lumpur, with a campus that integrates classroom, laboratory, and field-testing environments. Companies engage through co-located labs, on-campus testbeds, and university-run farms that enable prototyping and trials close to production supply chains. Health system integration and proximity to Putrajaya’s ministries and the Cyberjaya tech corridor facilitate collaboration and timely access to partners. Research is supported by competitive funding from Malaysia’s Ministry of Higher Education, the Ministry of Science, Technology and Innovation, and international sponsors. A dedicated technology transfer office manages IP, licensing, and startup support, connecting companies with faculty expertise and specialized facilities.
delivered to your inbox.